{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:55:20Z","timestamp":1791388520390,"version":"4.3.3"},"reference-count":147,"publisher":"Elsevier","isbn-type":[{"value":"9780443431906","type":"print"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["DDR\/IIRP23\/0771"],"award-info":[{"award-number":["DDR\/IIRP23\/0771"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/bs.pmbts.2026.01.002","type":"book-chapter","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:22:38Z","timestamp":1769170958000},"page":"361-403","source":"Crossref","is-referenced-by-count":0,"title":["Live biotherapeutics in cancer therapy"],"prefix":"10.1016","author":[{"given":"Rasmita","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreelakshmi S.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.\u00a0Sayamsmruti","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumendu","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2026.01.002_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115579","article-title":"Designing live bacterial therapeutics for cancer","volume":"221","author":"Lee","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib2","doi-asserted-by":"crossref","first-page":"1447176","DOI":"10.3389\/fbioe.2024.1447176","article-title":"From competition to cure: the development of live biotherapeutic products for anticancer therapy in the iGEM competition","volume":"12","author":"Van den Berghe","year":"2024","journal-title":"Front Bioeng Biotechnol"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.002_bib3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/0008-5472.CAN-22-2626","article-title":"Live biotherapeutic products as cancer treatments","volume":"83","author":"Brevi","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumour treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"33","key":"10.1016\/bs.pmbts.2026.01.002_bib5","doi-asserted-by":"crossref","first-page":"55736","DOI":"10.18632\/oncotarget.18469","article-title":"Tumour reductive therapies and antitumour immunity","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115663","article-title":"Bioinspired approaches to encapsulate and deliver bacterial live biotherapeutic products","volume":"225","author":"Brittain","year":"2025","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.002_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119726","article-title":"Bacterial therapy of cancer: a way to the dustbin of history or to the medicine of the future?","volume":"24","author":"Ikryannikova","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-023-01406-7","article-title":"Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications","volume":"8","author":"Zhao","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/iju.13538","article-title":"Bacillus Calmette-Guerin strain differences as the basis for immunotherapies against bladder cancer","volume":"25","author":"Miyazaki","year":"2018","journal-title":"Int J Urol"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15430\/JCP.23.036","article-title":"Efficacy of Bacillus Calmette-Guerin in cancer prevention and its putative mechanisms","volume":"29","author":"Gupta","year":"2024","journal-title":"J Cancer Prev"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcancer.2024.03.003","article-title":"Hypoxia-targeting bacteria in cancer therapy","volume":"100","author":"Staedtke","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/srep00436","article-title":"Explicit hypoxia targeting with tumour suppression by creating an \u201cobligate\u201d anaerobic Salmonella Typhimurium strain","volume":"2","author":"Yu","year":"2012","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumours: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cels.2018.06.008","article-title":"Synthetic biology and engineered live biotherapeutics: toward increasing system complexity","volume":"7","author":"Ozdemir","year":"2018","journal-title":"Cell Syst"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.20892\/j.issn.2095-3941.2023.0009","article-title":"Smart drug delivery systems to overcome drug resistance in cancer immunotherapy","volume":"20","author":"Yi","year":"2023","journal-title":"Cancer Biol Med"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib16","doi-asserted-by":"crossref","first-page":"1633953","DOI":"10.3389\/fimmu.2025.1633953","article-title":"Overcoming resistant cancerous tumours through combined photodynamic and immunotherapy (photoimmunotherapy)","volume":"16","author":"Kah","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13741-023-00315-1","article-title":"Review of cancer therapies for the perioperative physician","volume":"12","author":"Dabo-Trubelja","year":"2023","journal-title":"Perioper Med (Lond)"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1158\/1940-6207.CAPR-16-0249","article-title":"The human microbiome and cancer","volume":"10","author":"Rajagopala","year":"2017","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"10.1016\/bs.pmbts.2026.01.002_bib19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","article-title":"Inflammation and colon cancer","volume":"138","author":"Terzic","year":"2010","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.002_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120503","article-title":"Transporter and Lysosomal mediated (Multi)drug resistance to tyrosine kinase inhibitors and potential strategies to overcome resistance","volume":"10","author":"de Klerk","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"7802","key":"10.1016\/bs.pmbts.2026.01.002_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41586-020-2080-8","article-title":"Mutational signature in colorectal cancer caused by genotoxic pks(+) E. coli","volume":"580","author":"Pleguezuelos-Manzano","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/bs.pmbts.2026.01.002_bib22","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/nm.2015","article-title":"A human colonic commensal promotes colon tumourigenesis via activation of T helper type 17 T cell responses","volume":"15","author":"Wu","year":"2009","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib23","doi-asserted-by":"crossref","first-page":"G601","DOI":"10.1152\/ajpgi.00316.2020","article-title":"The role of butyrate in surgical and oncological outcomes in colorectal cancer","volume":"320","author":"Hajjar","year":"2021","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00001574-200401000-00009","article-title":"Colorectal cancer in inflammatory bowel disease","volume":"20","author":"Krok","year":"2004","journal-title":"Curr Opin Gastroenterol"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.pmbts.2022.07.007","article-title":"An overview of cancer and the human microbiome","volume":"191","author":"Mahapatra","year":"2022","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib26","first-page":"40","article-title":"Gut microbiome as a potential biomarker of cancer risk in inflammatory bowel disease","volume":"26","author":"Jones","year":"2022","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118559","article-title":"Bacteria-mediated cancer therapy (BMCT): therapeutic applications, clinical insights, and the microbiome as an emerging hallmark of cancer","volume":"192","author":"Jayaprakash","year":"2025","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2024.100698","article-title":"Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer","volume":"47","author":"Chang","year":"2024","journal-title":"Biomed J"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib29","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184321","article-title":"The gut microbiome and cancer response to immune checkpoint inhibitors","volume":"135","author":"Gazzaniga","year":"2025","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/bs.pmbts.2026.01.002_bib30","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1073\/pnas.1918095117","article-title":"Targeted inhibition of gut bacterial beta-glucuronidase activity enhances anticancer drug efficacy","volume":"117","author":"Bhatt","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0297-0","article-title":"Bacteria-cancer interactions: bacteria-based cancer therapy","volume":"51","author":"Duong","year":"2019","journal-title":"Exp Mol Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib32","article-title":"Bacillus Calmette-Guerin immunotherapy for cancer","volume":"9","author":"Cardillo","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib33","doi-asserted-by":"crossref","first-page":"1293351","DOI":"10.3389\/fcimb.2023.1293351","article-title":"Salmonella enterica and outer membrane vesicles are current and future options for cancer treatment","volume":"13","author":"Perez Jorge","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-008-0555-9","article-title":"Salmonella typhimurium engineered to produce CCL21 inhibit tumour growth","volume":"58","author":"Loeffler","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.002_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/cgt.2008.48","article-title":"IL-18-producing Salmonella inhibit tumour growth","volume":"15","author":"Loeffler","year":"2008","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1200\/JCO.2002.20.1.142","article-title":"Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma","volume":"20","author":"Toso","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.002_bib37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s44320-024-00067-0","article-title":"Bacterial live therapeutics for human diseases","volume":"20","author":"Frutos-Grilo","year":"2024","journal-title":"Mol Syst Biol"},{"issue":"8","key":"10.1016\/bs.pmbts.2026.01.002_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/0141076813494196","article-title":"Live viruses to treat cancer","volume":"106","author":"Donnelly","year":"2013","journal-title":"J R Soc Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib39","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1038\/s41467-020-19322-7","article-title":"Engineering microrobots for targeted cancer therapies from a medical perspective","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.921972","article-title":"Probiotics and live biotherapeutic products aiming at cancer mitigation and patient recover","volume":"13","author":"Schemczssen-Graeff","year":"2022","journal-title":"Front Genet"},{"issue":"10","key":"10.1016\/bs.pmbts.2026.01.002_bib41","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"10.1016\/bs.pmbts.2026.01.002_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102100","article-title":"Salmonella as a promising curative tool against cancer","volume":"14","author":"Aganja","year":"2022","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/bs.pmbts.2026.01.002_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006692","article-title":"Tumour invasion of Salmonella enterica serovar Typhimurium is accompanied by strong hemorrhage promoted by TNF-alpha","volume":"4","author":"Leschner","year":"2009","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.imbio.2016.06.009","article-title":"Toll-like receptor stimulation in cancer: a pro- and anti-tumour double-edged sword","volume":"222","author":"Dajon","year":"2017","journal-title":"Immunobiology"},{"issue":"23","key":"10.1016\/bs.pmbts.2026.01.002_bib46","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1002\/cam4.4799","article-title":"Bacteria in cancer therapy: a new generation of weapons","volume":"11","author":"Fan","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib47","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12979-023-00383-3","article-title":"Toll-like receptor 4 (TLR4): new insight immune and aging","volume":"20","author":"Kim","year":"2023","journal-title":"Immun Ageing"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.953678","article-title":"Bacteria-derived chimeric toxins as potential anticancer agents","volume":"12","author":"Khoshnood","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116839","article-title":"The role of bacterial toxins and spores in cancer therapy","volume":"235","author":"Weerakkody","year":"2019","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/bs.pmbts.2026.01.002_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/toxins9080236","article-title":"Bacterial toxins for cancer therapy","volume":"9","author":"Zahaf","year":"2017","journal-title":"Toxins (Basel)"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.781800","article-title":"Pseudomonas exotoxin-based immunotoxins: over three decades of efforts on targeting cancer cells with the toxin","volume":"11","author":"Havaei","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.624759","article-title":"Use of Salmonella bacteria in cancer therapy: direct, drug delivery and combination approaches","volume":"11","author":"Badie","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib53","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/gt.2013.86","article-title":"Salmonella induce autophagy in melanoma by the downregulation of AKT\/mTOR pathway","volume":"21","author":"Lee","year":"2014","journal-title":"Gene Ther"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.002_bib54","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.7150\/jca.75163","article-title":"Downregulation of AKT\/mTOR signaling pathway for Salmonella-mediated autophagy in human anaplastic thyroid cancer","volume":"13","author":"Wu","year":"2022","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3390\/ijms16010439","article-title":"Connexin 43 suppresses tumour angiogenesis by down-regulation of vascular endothelial growth factor via hypoxic-induced factor-1alpha","volume":"16","author":"Wang","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/bs.pmbts.2026.01.002_bib56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3171\/2023.6.JNS23243","article-title":"Oncolytic viral therapy: a review and promising future directions","volume":"140","author":"Reddy","year":"2024","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14737140.2025.2474732","article-title":"Oncolytic virotherapy - a promising approach in cancer treatment","volume":"25","author":"Sharma","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib59","doi-asserted-by":"crossref","first-page":"1278011","DOI":"10.3389\/fimmu.2023.1278011","article-title":"Listeria monocytogenes: a promising vector for tumour immunotherapy","volume":"14","author":"Ding","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.trecan.2020.11.004","article-title":"Tweak to treat: reprograming bacteria for cancer treatment","volume":"7","author":"Sieow","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib61","unstructured":"Sanmukh DSG, Potential for Bacteriophages as Anticancer Agents."},{"issue":"18","key":"10.1016\/bs.pmbts.2026.01.002_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25189938","article-title":"Recent advances and mechanisms of phage-based therapies in cancer treatment","volume":"25","author":"Ooi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/bs.pmbts.2026.01.002_bib63","doi-asserted-by":"crossref","first-page":"2003572","DOI":"10.1002\/advs.202003572","article-title":"Bacteria-based cancer immunotherapy","volume":"8","author":"Huang","year":"2021","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib64","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/vms3.32","article-title":"A phase I clinical study to evaluate safety of orally administered, genetically engineered Salmonella enterica serovar Typhimurium for canine osteosarcoma","volume":"2","author":"Fritz","year":"2016","journal-title":"Vet Med Sci"},{"issue":"7","key":"10.1016\/bs.pmbts.2026.01.002_bib65","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41591-019-0498-z","article-title":"Programmable bacteria induce durable tumour regression and systemic antitumour immunity","volume":"25","author":"Chowdhury","year":"2019","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/bs.pmbts.2026.01.002_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/v15081645","article-title":"Oncolytic virus engineering and utilizations: cancer immunotherapy perspective","volume":"15","author":"Muthukutty","year":"2023","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13051202","article-title":"Cytokines meet phages: a revolutionary pathway to modulating immunity and microbial balance","volume":"13","author":"Cianci","year":"2025","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib68","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/1533034615581977","article-title":"Bifidobacteria expressing tumstatin protein for antitumour therapy in tumour-bearing mice","volume":"15","author":"Wei","year":"2016","journal-title":"Technol Cancer Res Treat"},{"issue":"7","key":"10.1016\/bs.pmbts.2026.01.002_bib69","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00262-011-1002-x","article-title":"Targeting tumour vasculature with novel Listeria-based vaccines directed against CD105","volume":"60","author":"Wood","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"49","key":"10.1016\/bs.pmbts.2026.01.002_bib70","doi-asserted-by":"crossref","first-page":"85772","DOI":"10.18632\/oncotarget.20486","article-title":"Escherichia coli Nissle 1917 engineered to express Tum-5 can restrain murine melanoma growth","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib71","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-4939-1538-5_7","article-title":"Delivery of siRNAs to cancer cells via bacteria","volume":"1218","author":"Ahmed","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.002_bib72","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00262-012-1256-y","article-title":"Antitumour effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma","volume":"61","author":"Jia","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"6529","key":"10.1016\/bs.pmbts.2026.01.002_bib73","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Faecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104967","article-title":"Faecal microbiota transplantation: no longer cinderella in tumour immunotherapy","volume":"100","author":"Yang","year":"2024","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/bs.pmbts.2026.01.002_bib75","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/ijc.32003","article-title":"Faecal microbiota transplantation in cancer management: current status and perspectives","volume":"145","author":"Chen","year":"2019","journal-title":"Int J Cancer"},{"issue":"6371","key":"10.1016\/bs.pmbts.2026.01.002_bib76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6264","key":"10.1016\/bs.pmbts.2026.01.002_bib77","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"Vetizou","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib78","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.002_bib79","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41568-018-0070-z","article-title":"Tumour-targeting bacteria engineered to fight cancer","volume":"18","author":"Zhou","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"6622","key":"10.1016\/bs.pmbts.2026.01.002_bib80","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.add9667","article-title":"Engineering bacteria as interactive cancer therapies","volume":"378","author":"Gurbatri","year":"2022","journal-title":"Science"},{"issue":"7614","key":"10.1016\/bs.pmbts.2026.01.002_bib81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature18930","article-title":"Synchronized cycles of bacterial lysis for in vivo delivery","volume":"536","author":"Din","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.002_bib82","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1073\/pnas.1414558112","article-title":"Quorum-sensing Salmonella selectively trigger protein expression within tumours","volume":"112","author":"Swofford","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104088","article-title":"Advancements in synthetic biology-based bacterial cancer therapy: a modular design approach","volume":"190","author":"Arboleda-Garcia","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib84","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1021\/acssynbio.1c00452","article-title":"Precise thermal regulation of engineered bacteria secretion for breast cancer treatment in vivo","volume":"11","author":"Li","year":"2022","journal-title":"ACS Synth Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib85","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202106669","article-title":"Spatiotemporally controllable distribution of combination therapeutics in solid tumours by dually modified bacteria","volume":"34","author":"Wang","year":"2022","journal-title":"Adv Mater"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib86","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1038\/s41467-023-39224-8","article-title":"Bioengineering of bacteria for cancer immunotherapy","volume":"14","author":"Nguyen","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib87","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1021\/sb4000965","article-title":"Quorum sensing-modulated AND-gate promoters control gene expression in response to a combination of endogenous and exogenous signals","volume":"3","author":"Shong","year":"2014","journal-title":"ACS Synth Biol"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib88","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.fmre.2024.11.001","article-title":"Engineered bacteria: strategies and applications in cancer immunotherapy","volume":"5","author":"Zhang","year":"2025","journal-title":"Fundam Res"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib89","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nmeth.2926","article-title":"Principles of genetic circuit design","volume":"11","author":"Brophy","year":"2014","journal-title":"Nat Methods"},{"issue":"9","key":"10.1016\/bs.pmbts.2026.01.002_bib90","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.tips.2022.02.002","article-title":"Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics","volume":"43","author":"Lynch","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.002_bib91","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.chembiol.2014.10.008","article-title":"Quorum-sensing crosstalk-driven synthetic circuits: from unimodality to trimodality","volume":"21","author":"Wu","year":"2014","journal-title":"Chem Biol"},{"issue":"6","key":"10.1016\/bs.pmbts.2026.01.002_bib92","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"Kuhn","year":"2008","journal-title":"PLoS One"},{"issue":"21-22","key":"10.1016\/bs.pmbts.2026.01.002_bib93","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1089\/hum.2022.178","article-title":"Engineering cancer selective virotherapies: are the pieces of the puzzle falling into place?","volume":"33","author":"Swift","year":"2022","journal-title":"Hum Gene Ther"},{"issue":"7","key":"10.1016\/bs.pmbts.2026.01.002_bib94","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.947872","article-title":"Healing after death: antitumour immunity induced by oncolytic adenoviral therapy","volume":"3","author":"Jiang","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3389\/fmed.2020.00237","article-title":"Live biotherapeutic products, a road map for safety assessment","volume":"7","author":"Rouanet","year":"2020","journal-title":"Front Med (Lausanne)"},{"issue":"7741","key":"10.1016\/bs.pmbts.2026.01.002_bib96","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib97","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12864-021-07539-9","article-title":"Whole-genome analysis of probiotic product isolates reveals the presence of genes related to antimicrobial resistance, virulence factors, and toxic metabolites, posing potential health risks","volume":"22","author":"Wang","year":"2021","journal-title":"BMC Genomics"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib98","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/gutjnl-2024-334501","article-title":"Development of live biotherapeutic products: a position statement of Asia-Pacific microbiota consortium","volume":"74","author":"Tseng","year":"2025","journal-title":"Gut"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib99","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-020-15508-1","article-title":"Developing a new class of engineered live bacterial therapeutics to treat human diseases","volume":"11","author":"Charbonneau","year":"2020","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/bs.pmbts.2026.01.002_bib100","first-page":"903","article-title":"Organoid models in oncology: advancing precision cancer therapy and vaccine development","volume":"22","author":"Xiao","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"11","key":"10.1016\/bs.pmbts.2026.01.002_bib101","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.medj.2024.08.010","article-title":"Patient-derived organoids in precision cancer medicine","volume":"5","author":"Tong","year":"2024","journal-title":"Med"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib102","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1021\/acsbiomaterials.5c00247","article-title":"Preclinical assessment of living therapeutic materials: state-of-art and challenges","volume":"11","author":"Desai","year":"2025","journal-title":"ACS Biomater Sci Eng"},{"issue":"12 2","key":"10.1016\/bs.pmbts.2026.01.002_bib103","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1093\/infdis\/jiaa779","article-title":"Opportunities and challenges in development of live biotherapeutic products to fight infections","volume":"223","author":"Ducarmon","year":"2021","journal-title":"J Infect Dis"},{"issue":"18","key":"10.1016\/bs.pmbts.2026.01.002_bib104","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184466","article-title":"Preclinical testing techniques: paving the way for new oncology screening approaches","volume":"15","author":"van Rijt","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib105","article-title":"Entering first-in-human clinical study with a single-strain live biotherapeutic product: input and feedback gained from the EMA and the FDA","volume":"8","author":"Paquet","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10.1016\/bs.pmbts.2026.01.002_bib106","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/s12276-020-0437-6","article-title":"Live biotherapeutic products: the importance of a defined regulatory framework","volume":"52","author":"Cordaillat-Simmons","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102801","article-title":"Drugging the microbiome and bacterial live biotherapeutic consortium production","volume":"78","author":"McChalicher","year":"2022","journal-title":"Curr Opin Biotechnol"},{"issue":"2","key":"10.1016\/bs.pmbts.2026.01.002_bib108","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumours","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib109","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40265-023-01846-z","article-title":"Nadofaragene firadenovec: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-025-01664-8","article-title":"IL-15: from discovery to FDA approval","volume":"18","author":"Li","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"25","key":"10.1016\/bs.pmbts.2026.01.002_bib111","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib112","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib113","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41598-018-36926-8","article-title":"The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is a potent immunostimulant","volume":"9","author":"Laute-Caly","year":"2019","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/bs.pmbts.2026.01.002_bib114","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/1078-0432.CCR-23-0118","article-title":"Phase I Study of SYNB1891, an Engineered E. coli nissle strain expressing STING agonist, with and without atezolizumab in advanced malignancies","volume":"29","author":"Luke","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6667","key":"10.1016\/bs.pmbts.2026.01.002_bib115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.add7034","article-title":"Probiotic-guided CAR-T cells for solid tumour targeting","volume":"382","author":"Vincent","year":"2023","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib116","doi-asserted-by":"crossref","first-page":"1455163","DOI":"10.3389\/fimmu.2024.1455163","article-title":"Oncolytic virus and CAR-T cell therapy in solid tumours","volume":"15","author":"Ponterio","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104141","article-title":"Bacteria-driven cancer therapy: exploring advancements and challenges","volume":"191","author":"Din","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/bs.pmbts.2026.01.002_bib118","article-title":"Bacterial-based cancer therapy (BBCT): recent advances, current challenges, and future prospects for cancer immunotherapy","volume":"9","author":"Gupta","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib119","first-page":"37","article-title":"Bacteria-mediated synergistic cancer therapy: small microbiome has a big hope","volume":"13","author":"Lou","year":"2021","journal-title":"Nanomicro Lett"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib120","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jconrel.2017.10.041","article-title":"Doxorubicin-conjugated Escherichia coli Nissle 1917 swimmers to achieve tumour targeting and responsive drug release","volume":"268","author":"Xie","year":"2017","journal-title":"J Control Rel"},{"issue":"7","key":"10.1016\/bs.pmbts.2026.01.002_bib121","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nbt.1547","article-title":"Sequential treatment of drug-resistant tumours with targeted minicells containing siRNA or a cytotoxic drug","volume":"27","author":"MacDiarmid","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/bs.pmbts.2026.01.002_bib122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: a current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J Virol"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib123","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib124","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1038\/srep03394","article-title":"New paradigm for tumour theranostic methodology using bacteria-based microrobot","volume":"3","author":"Park","year":"2013","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib125","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40425-018-0381-3","article-title":"White paper on microbial anti-cancer therapy and prevention","volume":"6","author":"Forbes","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib126","article-title":"Hydrogels as promising platforms for engineered living bacteria-mediated therapeutic systems","volume":"16","author":"Yu","year":"2022","journal-title":"Mater Today Bio"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib127","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumour microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib128","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/sb500258b","article-title":"Synthetic microbes as drug delivery systems","volume":"4","author":"Claesen","year":"2015","journal-title":"ACS Synth Biol"},{"issue":"19","key":"10.1016\/bs.pmbts.2026.01.002_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194945","article-title":"Recent advances in bacteria-based cancer treatment","volume":"14","author":"Wei","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s42003-023-04496-9","article-title":"A design of experiments screen reveals that Clostridium novyi-NT spore germinant sensing is stereoflexible for valine and its analogs","volume":"6","author":"Sundaresan","year":"2023","journal-title":"Commun Biol"},{"issue":"30","key":"10.1016\/bs.pmbts.2026.01.002_bib131","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/j.vaccine.2009.04.041","article-title":"The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix","volume":"27","author":"Maciag","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib132","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2019.01.037","article-title":"Genetically engineered Salmonella Typhimurium: recent advances in cancer therapy","volume":"448","author":"Liang","year":"2019","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/bs.pmbts.2026.01.002_bib133","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.7150\/thno.21575","article-title":"E. coli Nissle 1917-derived minicells for targeted delivery of chemotherapeutic drug to hypoxic regions for cancer therapy","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib134","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3892\/ijo.2013.1790","article-title":"Clostridium butyricum MIYAIRI 588 shows antitumour effects by enhancing the release of TRAIL from neutrophils through MMP-8","volume":"42","author":"Shinnoh","year":"2013","journal-title":"Int J Oncol"},{"issue":"6","key":"10.1016\/bs.pmbts.2026.01.002_bib135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002203","article-title":"Phase I trial of intratumoural PVSRIPO in patients with unresectable, treatment-refractory melanoma","volume":"9","author":"Beasley","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/bs.pmbts.2026.01.002_bib137","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41591-025-03745-0","article-title":"Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Ralpha2 in recurrent glioblastoma: a phase 1 trial","volume":"31","author":"Bagley","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib138","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.omtm.2022.07.014","article-title":"Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. pylori immunostimulatory bacterial transgene","volume":"26","author":"Viker","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.1016\/bs.pmbts.2026.01.002_bib139","article-title":"Cell-derived Newcastle disease virus variant with two amino acid substitutions near cleavage site of F shows favorable traits as oncolytic virus","volume":"33","author":"Huberts","year":"2025","journal-title":"Mol Ther Oncol"},{"issue":"4","key":"10.1016\/bs.pmbts.2026.01.002_bib140","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.cell.2024.12.010","article-title":"Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients","volume":"188","author":"Zhong","year":"2025","journal-title":"Cell"},{"issue":"14","key":"10.1016\/bs.pmbts.2026.01.002_bib141","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115547","article-title":"Oncolytic virus therapy for glioma: current clinical trials and overcoming key obstacles","volume":"166","author":"Zhang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib143","first-page":"69","article-title":"Reovirus in cancer therapy: an evidence-based review","volume":"3","author":"Clements","year":"2014","journal-title":"Oncolytic Virother"},{"issue":"9","key":"10.1016\/bs.pmbts.2026.01.002_bib144","article-title":"Dose considerations for vaccinia oncolytic virus based on retrospective reanalysis of early and late clinical trials","volume":"12","author":"Cyrelle Ornella","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"19","key":"10.1016\/bs.pmbts.2026.01.002_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194703","article-title":"Dual-armed oncolytic myxoma virus encoding IFN-gamma and CD47 promotes lymphocyte infiltration and tumour suppression of syngeneic murine melanoma","volume":"15","author":"Woo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/bs.pmbts.2026.01.002_bib146","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2012.02.008","article-title":"Clinical development of Listeria monocytogenes-based immunotherapies","volume":"39","author":"Le","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/bs.pmbts.2026.01.002_bib147","series-title":"Microbiome Therapeutics","first-page":"289","article-title":"Chapter 11 - Overview of microbial therapeutics in immunological disorders","author":"Mishra","year":"2023"}],"container-title":["Progress in Molecular Biology and Translational Science","Live Biotherapeutics: Advancing Microbial Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117326000025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117326000025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:29:05Z","timestamp":1791386945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117326000025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9780443431906"],"references-count":147,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2026.01.002","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}